Inflammatory insults following islet transplantation (ITx) hinders engraftment and long-term function of the transplanted (Tx) islets. Using a murine model of ITx, we determined the role of LMP-420, a novel TNF-α inhibitor, both individually and in combination with the immunosuppressant cyclosporine A (CSA) in islet engraftment and survival. Diabetic C57BL/6 mice were Tx with 500 BALB/c islets under the kidney capsule. Four cohorts were used: LMP-420 only, CSA only, combination of LMP-420 and CSA (LMP+CSA), and control (n = 12 per cohort). Serial monitoring of blood glucose levels revealed that LMP+CSA (35 ± 5 days) prolonged stable blood insulin levels compared to control (6 ± 4 days). Immunohistology demonstrated that coadministration (LMP+CSA) results in a significant decrease in CD8 + T-cell infiltration (LMP+CSA: 31 ± 18 vs. control: 224 ± 51 cells, p < 0.001). Serum cytokine analysis revealed that LMP-420 administration resulted in an increase in the anti-inflammatory cytokine IL-10 (2.5-fold), and a decrease in TNF-α (threefold) with no change in IL-2. However, coadministration resulted in a marked decrease in both IL-2 and TNF-α (threefold) along with increase in . Coadministration also demonstrated increase of antiapoptotic SOCS-1 and Mn-SOD expression and significant reduction of donor-specific antibodies (p < 0.005). In conclusion, LMP-420 administration with CSA results in the upregulation of anti-inflammatory and antiapoptotic mechanisms which facilitate islet allograft engraftment and survival.
INTRODUCTION
anoxia (42, 43, 45) . This initial insult, resulting from a proinflammatory milieu, predisposes to alloimmuneand autoimmune-mediated damage of the transplanted Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the destruction of insulin-islets (14) . Therefore, one of the immediate goals in ITx is to identify novel strategies to prevent early damage of producing β-islets of the pancreas (41). Parenteral insulin administration still remains the major therapeutic these islets. Among the factors that limit islet graft survival are strategy for treatment of patients with T1DM (31) . However, this approach leads to long-term complications inflammatory cytokines, mainly interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-such as diabetic retinopathy, nephropathy, neuropathy, and macrovascular disease (30) . Islet transplantation α), which are released by the infiltrating mononuclear cells (7) . TNF-α inhibitors have proven efficacious (ITx) has been proposed to be an effective treatment to achieve sustained blood glucose levels in T1DM towards the treatment and modulation of inflammatory and autoimmune responses in diseases such as rheuma-patients. However, even with the use of immunosuppressive agents, the long-term success of islet allografts still toid arthritis and psoriasis (44) . LMP-420 is a novel anti-inflammatory purine nucleobase analogue that tran-remains poor with <10% 5-year survival (21, 42) . One of the major reasons for loss of islet function immediately scriptionally inhibits TNF-α production (18). LMP-420 is noncytotoxic to TNF-α-producing cells and does not posttransplant is inflammation caused by ischemia and bind to or interfere with the activity of preformed TNF-kit (Mercodia Inc., Winston Salem, NC). Serum obtained (stored at −20°C) from 60-80 µl blood col-α (28) . In addition, studies have shown that LMP-420 inhibits several of the IFN-γ-induced chemokines such lected by retro-orbital puncture was used. Standard insulin solution and serum (25 µl) were added into a as CXC chemokine ligand-9 (CXCL-9) and CXCL-10 (17) . Based on these unique properties, we postulated monoclonal anti-insulin antibody (Ab)-coated ELISA plate along with enzyme conjugate and incubated for 2 that administration of LMP-420 following ITx would be beneficial in preventing damage to the islets and that h at room temperature. After washing six times, TMB (3,3′,5,5″-tetramethylbenzidine) substrate (200 µl) was such treatment might synergize with a currently utilized immunosuppressive regimen in prolonging islet allograft added and incubated for another 5 min. The reaction was stopped by adding 50 µl of stopping solution and read survival. Our results demonstrate that administration of LMP-420 significantly reduces early islet cell loss post-at 450 nm on a microplate reader. Serum levels of cytokines were analyzed using a mul-Tx leading to restoration of normoglycemia in chemically induced diabetic animals. We also demonstrate that tiplex bead immunoassay (Biosource International Inc., Camarillo, CA) as per the manufacturer's protocol (10) . the beneficial effect of LMP-420 is mediated by its potent anti-inflammatory and antiapoptotic pathways.
Briefly, primary Ab-coated beads with standards and samples were incubated for 2 h at room temperature. The Furthermore, LMP-420 acts synergistically with the commonly used immunosuppressive, calcineurin inhibi-wells were washed and incubated with biotinylated Abs for 30 min. The streptavidin-R-phycoerythrin solution tor cyclosporin A (CSA), to further enhance the survival of allogeneic transplanted islets.
was added and read using the Luminex-xMAP-system.
MATERIALS AND METHODS

Analysis of T-Cell Frequency Animals and Induction of Diabetes
Transplanted mice splenocytes were stimulated with Six-to 8-week-old C57BL/6 (H2 b ) and BALB/c irradiated donor splenocytes; the number of T cells (H2 d ) mice were purchased from Jackson Laboratories.
secreting IFN-γ, IL-10, IL-4, and TNF-α was enumer-Animal studies were performed in accordance with the ated by ELISPOT (Enzyme-linked immunosorbent spot) Animal Studies Committee, Washington University, St.
(5). Briefly, Millipore MultiScreen filter plates (Milli-Louis, MO guidelines. Streptozotocin (STZ, Sigma, St.
pore Corporation, Billerica, MA) were coated overnight Louis, MO, 200 mg/kg) was administered intraperitonewith 5 µg/ml capture mouse cytokine-specific mAb (BD ally (IP) to induce diabetes in C57BL/6 mice. Nonfast-Biosciences Pharmingen TM , San Diego, CA). Subseing blood glucose (NFBG) was measured using tail snip quently, 3 × 10 5 recipient splenocytes were cultured in (One Touch II-glucometer; Lifescan Inc., Milpitas, CA).
triplicate in the presence of irradiated donor splenocytes Mice with two consecutive NFBG ≥ 400 mg/dl were (1:1 ratio). After 48-72 h, 2 µg/ml biotinylated mAb considered diabetic.
was added to the wells and incubated overnight. The Islet Isolation, Transplantation, and Treatment plates were washed and 100 µl streptavidin-horseradish Islets from murine pancreata were isolated by colperoxidase (HRP) was added. After 2 h, the assay was lagenase digestion and transplanted under the kidney developed by 3-amino-9-ethylcarbazole substrate reagent capsule as described previously (29). In brief, donor and the spots were analyzed. pancreata were digested using collagenase-XI (Sigma, 4 mg/ml). Islets washed and purified on a Ficoll-gradient Immunohistochemistry for Graft-Infiltrating CD4 + were handpicked and cultured for 24 h before Tx. The and CD8+ T Cells reversal of diabetes was defined as a reduction in con-Explanted kidneys containing transplanted islets were secutive NFBG <200 mg/dl post-ITx, and rejection was embedded in frozen tissue matrix and sections cut at a defined as an increase in NFBG >250 mg/dl. LMP-420 6-µm thickness. They were fixed in cold alcohol for 2 (96-98%) was synthesized by Scynexis Inc. (Research min (−20°C), air dried, treated with 3% H 2 O 2 , and Triangle Park, NC). The LMP-420 and CSA stock solublocked with biotin/avidin (Avidin/Biotin Blocking Kit; tions were made using 5% sorbitol (Sigma). The animals Vector Laboratories, Burlingame, CA). The sections were administered IP with either 5% sorbitol (n = 12) or were incubated overnight with rat anti-mouse mAbs LMP-420 alone (25 mg/kg, n = 12) or CSA alone (25 against cluster of differentiation 4 (CD4) and CD8 T mg/kg, n = 12) or a combination of LMP-420 and CSA cells (5.0 µg/ml, BD Biosciences Pharmingen TM ) or iso-(both 25 mg/kg, n = 12) every day from day −1 of ITx.
type Ab (Chemicon International, Billerica, MA).
Determination of Serum Insulin, Chemokines,
Washed sections were treated with biotin-conjugated and Cytokines goat anti-rat IgG followed by streptravidin-HRP. The presence of positive cells was detected with the DAB The concentrations of insulin were measured using an insulin ELISA (enzyme-linked immunosorbent assay) (3,3′-diaminodbenzidine) substrate kit (BD Biosciences Pharmingen TM ). Photomicrographs were taken of 10 ran-min at 4°C. Anti-mouse phycoerythrin (PE)-labeled secondary Ab was added and further incubated for 30 min. dom field stained sections using a Nikon Eclipse 50i microscope (10×) from each group and were analyzed The cells were then washed and read on a fluorescenceactivated cell sorter (FACS) caliber machine with instru-using morphometric software (NIS-Elements BR 3.2 program) in a blinded fashion. Sections were also pre-mental settings for mouse splenocytes. pared from control islet grafts from nontreated mice Statistical Analysis with and without incubation with mouse CD4 + and CD8 + Abs.
Data are expressed as mean ± SD. Statistical differences between means were analyzed using a paired or Determination of SOCS-1 and Mn-SOD by RT-PCR unpaired Student's t-test, or subjected to Scheffe's post and Western Blots hoc test in analysis of variance (ANOVA). Using the A significant portion of pancreatic islet grafts can be Scheffe procedure all possible comparisons between the destroyed by apoptosis, failing to engraft in the early means of controls with individual treatment groups (LMPperiod immediately post-ITx. Overexpression of sup-420 alone, CSA alone, and LMP+CSA group) were conpressor of cytokine signaling-1 (SOCS-1) and mangaducted. A value of p < 0.05 was considered significant. nese-dependent superoxide dismutase (Mn-SOD) in islet grafts achieve an antiapoptotic effect to prolong graft RESULTS survival. Expression profiles of SOCS-1, Mn-SOD, and
LMP-420 and CSA Prolongs Islet Allograft Survival actin were analyzed by FAM-labeled RT-PCR primers
To determine the effect of LMP-420, diabetic (Applied Biosystems, Foster City, CA). Briefly, total C57BL/6 mice were treated with LMP-420 1 day prior RNA was extracted from islet grafts using TRIzol to ITx (500 BALB/c islets) and daily thereafter. As reagent. The RNA was reverse transcribed and real-time shown in Figure 1 , LMP-420 significantly prolonged RT-PCR was performed using iCycler 480 Probes Masislet allograft survival (22 ± 3 days), whereas the vehiter (Bio-Rad Laboratories, Inc., Hercules, CA). Cycling cle-treated cohort rejected the allograft on 7 ± 2 days conditions consisted of an initial denaturation of 95°C post-Tx (p = 0.005). To confirm that normoglycemia for 15 min, followed by 40 cycles of 95°C for 30 s, was achieved by the transplanted islets, a group of LMPfollowed by 61°C for 1 min. 420-treated mice was nephrectomized 14 days post-ITx. Protein levels of SOCS-1 and Mn-SOD were ana-Nephrectomy resulted in prompt elevation of NFBG levlyzed by Western blot. The graft extracts were obtained els, demonstrating that normoglycemia was being using 4% SDS cell lysis buffer containing protease achieved by the transplanted islets ( Fig. 1A) . Daily inhibitor cocktail. Extracts were boiled for 20 min in administration of CSA also significantly prolonged graft sample buffer [200 mmol/L Tris (pH 6.8), 20% glycerol, survival (24 ± 3 days) compared with control (p = 2% SDS, 0.1% bromophenol blue, and 10% β-mercapto-0.001) ( Fig. 1B) . These results demonstrate that LMPethanol], centrifuged for 30 min, and run on 4-12% gra-420 prolongs islet allograft survival similar to that dient Bis-Tris denaturing gels (NuPage; Invitrogen).
observed with CSA. The gels were transferred onto nitrocellulose membranes, and blocked overnight with 5% nonfat milk in Synergism of LMP-420 With Low-Dose CSA PBS-T (0.1% Tween20). Thereafter, the membranes in Prolonging Islet Allograft Survival were incubated for 1 h with the appropriate Abs. After labeling with HRP-labeled secondary Ab (1:10,000 dilu-
The above results demonstrated that either LMP-420 or CSA alone significantly prolonged islet allograft sur-tion; Jackson ImmunoResearch Laboratory Inc., West Grove, PA), the membranes were developed using vival. However, islets were rejected between days 23 and 27 post-Tx, respectively. Therefore, we sought to chemiluminescence detection kit (Millipore) and analyzed using Bio-Rad Universal Hood-II (Bio-Rad Labo-determine whether LMP-420 could act synergistically with CSA to prolong allograft survival. Combined treat-ratories, Inc.). Morphometric analysis was performed using the software provided by the company. ment (LMP+CSA) significantly prolonged allograft survival (35 ± 5 days; p = 0.0001) compared to control Detection of Donor-Specific Abs (DSA) in the (Fig. 1B) . These results demonstrate that combination of Recipient's Sera by Immunofluorescence the anti-inflammatory LMP-420 with immunosuppressive agents such as calcineurin inhibitors can result in Sera from sensitized C57BL/6 mice were assayed for allo-Abs by their ability to bind BALB/c splenocytes enhanced islet graft survival. Furthermore, the sera from the control cohort had significantly lower (p = 0.0002) using flow cytometry. Donor splenocytes (0.5 × 10 6 ) were incubated in 50 µl fluorescence-activated cell sor-( Fig. 2A ) insulin on day 8 compared with all three treatment cohorts (LMP, CSA, or LMP+CSA). All three ter (FACS) buffer (5% FBS, 1% HEPES, 0.2% sodiumazide in HBSS), containing 1:10 recipient serum for 30 treatment regimens demonstrated insulin levels up to 0.5 ± 0.1 pg/ml from day 8 through day 20. Addition-treatment cohorts reached pre-Tx levels by day 22, indicating the rejection. In contrast, the combined treatment ally, serial histology sections of transplanted islets from treatment groups showed positive staining for insulin on cohort retained high serum insulin levels at 32 days post-Tx, corresponding to the graft survival curve day 8, signifying the presence of functionally healthy islets ( Fig. 2B ). Insulin levels in LMP-420 and CSA ( Fig. 1B) . LMP-420, CSA, and LMP+CSA Administration Delay LMP+CSA were significantly decreased compared to control (p = 0.0007) as well as LMP-420-or CSAthe Infiltration of Donor-Specific CD4 + and CD8 + Cells Into the Islet Grafts treated cohorts (p = 0.004). These results demonstrate that the infiltration of T cells into the allograft was sig-To identify the kinetics and specificity of cells infilnificantly reduced when LMP-420 is combined with trating the islet allografts, we performed immunohistol-CSA, which agrees with the prolonged islet allograft ogy of the grafts on day 8 post-Tx, a time point when survival noted with this regimen. controls start rejecting. Grafts from normoglycemic mice were removed from all three treatment cohorts and Administration of LMP-420 or CSA and Combined sections were stained for CD4 + and CD8 + cells. As Treatment Leads to Decreased Production shown in Figure 3 , the control grafts showed marked of Proinflammatory Mediators infiltrating CD4 + and CD8 + cells (152 ± 42 and 224 ± 51
Ischemia-reperfusion injury results in increased procells, respectively, p = 0.0001) enumerated by morphoduction of proinflammatory cytokines that accelerate metric analysis using NIS-Elements BR 3.2 software. In islet cell death (5, 13) . To test whether LMP-420, CSA, contrast, the LMP-420 and CSA groups had 42 ± 20, and the combination decreases the levels of inflamma-58 ± 30 and 76 ± 24, 112 ± 42 CD4 + and CD8 + cells, tory cytokines and chemokines, sera collected from all respectively, which though reduced was not very signififour groups on day 8 post-Tx were analyzed using a cantly different from controls. In contrast, infiltra-Mouse Twenty-plex Luminex kit. As shown in Figure  tions of CD4 + and CD8 + cells (22 ± 10 and 31 ± 18 4A, cytokines IL-1β and IL-4 were 1.3-to 2-fold lower cells, respectively) following combined treatment with in all three treatment cohorts compared to control (p = 0.01). Furthermore, the T-cell proliferative cytokine IL-2 was 2.5-to 3-fold lower in the CSA and LMP+CSA cohorts (p = 0.01) but not in the LMP-420 treatment cohort compared to control (144 ± 18 vs. 178 ± 21 pg/ ml, p = 0.145). In contrast, serum IL-10 levels in the LMP-420 treatment cohort were 2.5-fold (221 ± 9.8 vs. 86 ± 14.3 pg/ml, p = 0.0001) and 1.6-fold (221 ± 9.8 vs. 136 ± 18 pg/ml, p = 0.004) higher than those in the control and CSA administered mice, respectively. Furthermore, the LMP+CSA group had 3-fold higher concentrations of IL-10 in their sera compared to controls (86 ± 14.3 vs. 240.6 ± 35 pg/ml, p = 0.00001), indicating a potentially significant role for LMP-420 in increasing IL-10-mediated anti-inflammatory effects. Additionally, LMP-420 alone and LMP+CSA cohorts had 3-and 2fold reductions of TNF-α, respectively, in their sera compared with the control cohort (p = 0.001). The CSA alone-treated group also showed a decrease in TNF-α concentration (372.3 ± 47 vs. 284.3 ± 27 pg/ml, p < 0.05) compared to controls. Chemokines produced after Tx play a pivotal role in recruitment of inflammatory cells (25) . To determine the effect of LMP-420 on chemokine production, sera were analyzed for the levels of chemokines that play critical roles in directing mononuclear cells to islet allografts (48) . As depicted in Figure 4B , LMP-420 and LMP+CSA decreased the levels of IFN-γ-inducible protein-10 (IP-10), monocyte chemotactic protein-1 (MCP- induced by IFN-γ (MIG) were found to be significantly less (1.6-to 2.5-fold, p < 0.001) in all LMP-420, CSA, 0.01), whereas the CSA alone group demonstrated a 1.3fold decrease (p < 0.05) (Fig. 5D ). In contrast, LMP-and LMP+CSA treatment groups compared to controls. 420, CSA, and LMP+CSA groups had 2-, 1.4-, and 2.4-fold increases in the frequency of IL-10-producing
Low Frequency of Donor Reactive T-Cells
T cells, respectively (Fig. 5B ), compared to controls. in the Recipient Spleen After Treatment These ELISPOT results correlated well with the With LMP-420, CSA, and LMP+CSA decreased levels of proinflammatory and increased lev-To study the effect of treatment with the above agents els of anti-inflammatory cytokines in the sera of treaton the initiation of alloimmune responses after ITx, we ment cohorts. determined the frequency of IL-4-, IL-10-, IFN-γ-, and
TNF-α-secreting T cells upon stimulation with donor
Enhanced SOCS-1 and Mn-SOD Levels With LMP cells by ELISPOT on day 8 post-Tx (Fig. 5 ). We and CSA Combination observed 2.3-, 2-, and 4.1-fold reductions (p < 0.001) in the frequency of IL-4-producing T cells in LMP-420, The results presented above indicated enhanced production of anti-inflammatory molecules after treatment CSA, and LMP+CSA compared with controls, respectively (Fig. 5A) . Similarly, the IFN-γ-producing T-cell with LMP-420 and CSA. To further determine the potential mechanisms involved in prolonged allograft frequency was reduced by 1.6-, 2.0-, and 2.9-fold (p < 0.001) compared with control, respectively (Fig. 5C ).
survival, we analyzed for the expression of SOCS-1 and Mn-SOD, two important molecules involved in the pre-The frequency of TNF-α-producing T cells in LMP-420 and LMP+CSA administered mice was 3-fold less (p < vention of islet apoptosis. Mn-SOD is a mitochondrial antioxidant enzyme, increased expression of which pro-alone (4.3 ± 1.1 and 3.2 ± 0.5, respectively) ( Fig.6C, D) . In addition, blinded morphometric analysis of the tects islet cells from inflammatory damage (19). The transcription factor SOCS-1 has the ability to negatively explanted islet grafts (day 8) upon terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining regulate inflammatory cytokine signaling and can also inhibit islets apoptosis through suppression of the Janus demonstrated 3.2-fold (12 ± 7 vs. 47 ± 13 cells) decreased numbers of apoptotic cells in LMP+CSA kinase-signal transducer and activator of transcription (JAK-STAT) pathway (23) . The effect of combined treatment group (data not shown) compared to the control, respectively. These results further support that treatment with LMP+CSA on the intracellular expression of these molecules was determined using both LMP-420 induces upregulation of the antiapoptotic and anti-inflammatory transcriptional factors Mn-SOD and Western blot and RT-PCR analyses of explanted grafts on day 8 post-Tx. As shown in Figure 6A and B, West-SOCS-1, which is beneficial for the continued function of transplanted islets. ern blot and densitometry analysis clearly demonstrated that there are 2.8 ± 0.6-and 1.6 ± 0.4-fold increases in LMP-420, CSA, and LMP+CSA Administration Delay the levels of SOCS-1 and Mn-SOD (p < 0.001) in allo-Formation of Abs to Donor Major Histocompatibility grafts from LMP-420-treated mice. Furthermore, the Complex (MHC) (DSA) in the Recipient LMP+CSA demonstrated a very significant 6.2 ± 0.6and 4.3 ± 0.5-fold increase of SOCS-1 and Mn-SOD Even after continued treatment with LMP-420 and LMP+CSA allograft rejection occurred at 23 and 35 levels, respectively (p < 0.0001). RT-PCR analysis of mRNA expression levels of SOCS-1 and Mn-SOD in days post-Tx, respectively. Studies from our laboratory, and others, have shown that the development of DSA treatment cohorts also demonstrated enhanced expression of these transcription factors (11.8 ± 3.1 and 6.8 ± correlates with the rejection of transplanted islets (6, 29) . Therefore, sera collected at the time when glucose levels 2.1, respectively) with coadministration over LMP-420 were rising were analyzed for development of DSA by and Tx procedures (4,22,38). Prior to vascularization, transplanted islets are susceptible to inflammation and FACS. The sera of mice treated with LMP-420 or CSA alone showed DSA on day 22 post-Tx (Fig. 7A, B ). This apoptosis due to lack of nutrition and compromised blood flow. Furthermore, the processes of coagulation paralleled the increase in NFBG and decreased insulin levels, indicating rejection of transplanted islets. In con-and thrombosis contribute to multiple insults suffered by the islets during early post-Tx period (38) . These factors trast, LMP+CSA-treated sera showed no Abs binding to the donor splenocytes on day 22 (Fig. 7C) , with both induce inflammation, apoptosis, and loss of islets, subsequently inducing adaptive immune responses that com-normoglycemia and insulin levels significantly higher, indicating functional islets. However, the presence of promise the long-term survival. It is estimated that up to 70% of the islets are lost in the early post-Tx period, DSA was detected on day 33, when all the mice became hyperglycemic (Fig. 7D) . These results indicate that com-contributing to the need for islets from multiple pancreata to achieve insulin independence in a single recipi-bined treatment of LMP-420 with CSA can not only downregulate the cellular immune recognition of the graft but ent (2). Interest in clinical ITx has contributed to development of improved harvesting, purification proce-also delay the humoral response against the graft.
dures, and new steroid-free immunosuppressive drug DISCUSSION regimens that minimize β-cell toxicity and insulin resistance (45) . This has resulted in excellent rates of engraft-Islet transplants are subjected to ischemia and reperfusion injuries as a consequence of both their isolation ment and achievement of normoglycemia. Nonetheless, recent longer term follow-up data of ITx recipients have upregulation of both the transcriptional and protein levels of SOCS-1 and Mn-SOD, two molecules previously shown that most recipients who are rendered free from insulin therapy at 1 year need to reinstitute insulin ther-demonstrated to be important in allograft survival (11, 24) . Initial insult to β-cells following the Tx reduces their apy within 5 years post-Tx (42).
Traditionally, CSA is an immunomodulator that is functional efficiency. In our murine model, animals continually treated with LMP-420 and CSA showed better effectively utilized to prevent rejection in solid organ Tx such as heart, liver, and kidney (3, 9, 12) . It has a high islet allograft survival as evidenced by continued normoglycemia and increased serum insulin levels (Figs. 1 specificity for T lymphocytes and inhibits cell-mediated immune responses. We previously identified a novel and 2). Proinflammatory cytokines have been shown to play a significant role in acute graft rejection. Pascher small molecule, LMP-420, which effectively inhibits TNF-α production both in vitro and in vivo (17) . In our et al. (33) demonstrated that anti-TNF therapy attenuated the acute rejection episode. Studies have shown that current study using a murine model of ITx we demonstrate that a combination of LMP-420 with low-dose the local expression of the inflammatory cytokine TNFα can impair tolerance to both auto-and alloreactivity CSA results in enhanced islet engraftment resulting in significant prolongation of islet allograft function. This (46). Endogenous overexpression of TNF-α resulted in accelerated rejection of transplanted islets in both auto-enhanced engraftment is a result of both downregulation of proinflammatory cytokines/chemokines and upregula-immune and chemically induced diabetic mice, compared to wild-type, by accelerating the infiltration of tion of anti-inflammatory cytokines/chemokines. More importantly, this combined treatment results in the CD4 + and CD8 + T cells (34). Our results demonstrate ( Fig. 3 ) reduced infiltration of both CD4 + and CD8 + T Previous studies from our laboratory, and studies by others, have demonstrated that Abs to HLA in human cells by 70% on day 8 following administration of LMP-420 alone. However, coadministration of LMP-420 and ITx has a positive correlation with graft rejection (8, 27, 40) . Studies in animal models of ITx also indicate CSA reduced the T-cell infiltration by 95%. This decreased cellular infiltration and significantly decreased that Tx across sensitization to major histocompatibility (MHC) antigens is unfavorable towards islet allograft serum TNF-α noted following administration of LMP-420 indicated that these mechanisms play an important survival and function (6) . Earlier studies in our laboratory demonstrated that ITx into MHC-mismatched STZ-role in the noted prolongation of islet allografts following LMP-420 administration.
treated diabetic mice resulted in the rejection of islets with mean survival time 2 days when compared to The role of proinflammatory responses in graft rejection is well defined (1,26). T cells are important in the unsensitized mice with mean survival time of 10 days (16) . In our current report, we demonstrate that the pathogenesis of rejection, and constitute a predominant infiltrating cell type. However, other mononuclear cell enhanced protection and survival is also evidenced by delayed circulating levels of DSA in the cotreatment subpopulations, including B cells, natural killer (NK) cells, and monocytes/macrophages also have been shown cohort. FACS analysis demonstrated appearance of DSA during the rejection (22 days post-Tx) in LMP-420 and to contribute in rejection (37,39). Proinflammatory cytokines/chemokines released from the initial infiltrating CSA alone groups while no DSA was detected in serum from cotreatment mice. The serum DSA development cells plays a major role in the continued infiltration of cells to the graft (5,20, 25, 49) . In this study we demon-was detected during the final stages of graft rejection (35 days post-Tx), indicating that combined treatment strated that LMP-420 not only attenuates proinflammatory TNF-α, IL-1β, and MCP-1 responses, but also not only downregulates cellular immune response but also delays the humoral immune response against the graft. augments an anti-inflammatory IL-10 response (Fig. 4) . We also demonstrated that the combination of LMP-420
Our results conclusively demonstrate that LMP-420 has a potent anti-inflammatory and antiapoptotic effect. and CSA provided a synergistic effect on the cytokine environment that facilitated islet allograft survival.
LMP-420 has been further demonstrated to enhance islet survival and function by inhibiting the alloimmune Thus, our results demonstrated that the delayed islet allograft rejection is due to a skewing of the equilibrium humoral and cellular responses. Based on our data, we propose a novel therapeutic application for LMP-420 in towards an enhanced IL-10 with decline in proinflammatory cytokines including TNF-α, IL-1β, IL-2, and combination with current therapeutic regimens using calcineurin inhibitors, such as CSA, in the amelioration IL-4. Based on our data, we conclude that regulatory mechanisms were induced by LMP-420, which inhibits of rejection following human islet transplantation. the proinflammatory TNF-α and simultaneously turns 
